Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial.

Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MF, Menefee SA, Schaffer J, Wei J, Chai T, Janz N, Spino C, Meikle S; Pelvic Floor Disorders Network.

Contemp Clin Trials. 2012 Jan;33(1):184-96. doi: 10.1016/j.cct.2011.09.019. Epub 2011 Oct 8.

2.

Minimum important difference for validated instruments in women with urge incontinence.

Dyer KY, Xu Y, Brubaker L, Nygaard I, Markland A, Rahn D, Chai TC, Stoddard A, Lukacz E; Urinary Incontinence Treatment Network (UITN).

Neurourol Urodyn. 2011 Sep;30(7):1319-24. doi: 10.1002/nau.21028. Epub 2011 May 11.

3.

Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial.

Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, Daniell G, Zhou J, Haag-Molkenteller C.

J Urol. 2010 Dec;184(6):2416-22. doi: 10.1016/j.juro.2010.08.021. Epub 2010 Oct 16.

PMID:
20952013
4.

Treatment of overactive bladder in women.

Hartmann KE, McPheeters ML, Biller DH, Ward RM, McKoy JN, Jerome RN, Micucci SR, Meints L, Fisher JA, Scott TA, Slaughter JC, Blume JD.

Evid Rep Technol Assess (Full Rep). 2009 Aug;(187):1-120, v. Review.

5.

Refractory idiopathic urge urinary incontinence and botulinum A injection.

Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, Barber MD, Menefee S, Schaffer J, Weber AM, Wei J; Pelvic Floor Disorders Network.

J Urol. 2008 Jul;180(1):217-22. doi: 10.1016/j.juro.2008.03.028. Epub 2008 May 21.

6.

Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial.

Staskin D, Sand P, Zinner N, Dmochowski R; Trospium Study Group.

J Urol. 2007 Sep;178(3 Pt 1):978-83; discussion 983-4. Epub 2007 Jul 16.

PMID:
17632131
7.

Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity.

Karsenty G, Reitz A, Lindemann G, Boy S, Schurch B.

Urology. 2006 Dec;68(6):1193-7. Epub 2006 Dec 4.

PMID:
17141831
8.

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.

Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003781. Review.

PMID:
17054185
9.

The responsiveness of the OAB-q among OAB patient subgroups.

Coyne KS, Matza LS, Thompson C, Jumadilova Z, Bavendam T.

Neurourol Urodyn. 2007;26(2):196-203.

PMID:
17016794
10.

Effectiveness of repeated treatment with botulinum toxin type A across different conditions.

Gordon MF, Barron R.

South Med J. 2006 Aug;99(8):853-61. Review.

PMID:
16929880
11.

Determining the importance of change in the overactive bladder questionnaire.

Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V.

J Urol. 2006 Aug;176(2):627-32; discussion 632.

PMID:
16813906
12.

Perceptions and behaviours of women with bladder control problems.

Diokno AC, Sand PK, Macdiarmid S, Shah R, Armstrong RB.

Fam Pract. 2006 Oct;23(5):568-77. Epub 2006 May 26.

PMID:
16731545
13.

Persistence with overactive bladder pharmacotherapy in a Medicaid population.

Shaya FT, Blume S, Gu A, Zyczynski T, Jumadilova Z.

Am J Manag Care. 2005 Jul;11(4 Suppl):S121-9.

14.
15.
17.

Impact of a health education intervention in overactive bladder patients.

Herschorn S, Becker D, Miller E, Thompson M, Forte L.

Can J Urol. 2004 Dec;11(6):2430-7.

PMID:
15636668
18.

Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.

Chapple CR, AraƱo P, Bosch JL, De Ridder D, Kramer AE, Ridder AM.

BJU Int. 2004 Jan;93(1):71-7. Erratum in: BJU Int. 2004 May;93(7):1135.

PMID:
14678372
19.

Validation of two global impression questionnaires for incontinence.

Yalcin I, Bump RC.

Am J Obstet Gynecol. 2003 Jul;189(1):98-101.

PMID:
12861145
20.

Prevalence and burden of overactive bladder in the United States.

Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ.

World J Urol. 2003 May;20(6):327-36. Epub 2002 Nov 15.

Supplemental Content

Support Center